With biotechnology continuing to be the hot sector heading into 2015, we've seen several investment firms looking to capitalize on the trend. I've profiled a pair of those new biotech ETFs launched just recently here and here and another new one targeting a specific niche of the biotech universe began trading at the end of October of last year.
The ARK Genomic Revolution Multi-Sector ETF (NYSEARCA:ARKG) is from ARK Capital Management. Its primary investment objective according to the fund's fact sheet is to identify securities that "are substantially focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in genomics into their business. One such way this is accomplished is by offering new products or services that rely on genomic sequencing, analysis, synthesis or instrumentation."
Click the button below to read the rest of this original article on Seeking Alpha.
Got a question? A comment? A fund you want to see profiled? Let us know!